NO20030393D0 - Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler - Google Patents

Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler

Info

Publication number
NO20030393D0
NO20030393D0 NO20030393A NO20030393A NO20030393D0 NO 20030393 D0 NO20030393 D0 NO 20030393D0 NO 20030393 A NO20030393 A NO 20030393A NO 20030393 A NO20030393 A NO 20030393A NO 20030393 D0 NO20030393 D0 NO 20030393D0
Authority
NO
Norway
Prior art keywords
azoles
anilines
ullmann coupling
efficient ligand
mediated ullmann
Prior art date
Application number
NO20030393A
Other languages
English (en)
Other versions
NO20030393L (no
Inventor
Jia Cheng Zhou
Pasquale N Confalone
Hui-Yin Li
Lynette M Oh
Lucius T Rossano
Charles G Clark
Christopher A Teleha
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20030393D0 publication Critical patent/NO20030393D0/no
Publication of NO20030393L publication Critical patent/NO20030393L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/38One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Executing Machine-Instructions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
NO20030393A 2000-07-26 2003-01-24 Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler NO20030393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22093200P 2000-07-26 2000-07-26
PCT/US2001/023541 WO2002008199A2 (en) 2000-07-26 2001-07-26 Efficient ligand-mediated ullmann coupling of anilines and azoles

Publications (2)

Publication Number Publication Date
NO20030393D0 true NO20030393D0 (no) 2003-01-24
NO20030393L NO20030393L (no) 2003-03-24

Family

ID=22825611

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030393A NO20030393L (no) 2000-07-26 2003-01-24 Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler

Country Status (22)

Country Link
US (1) US6541639B2 (no)
EP (1) EP1307431B1 (no)
JP (1) JP2004504384A (no)
KR (1) KR20030060872A (no)
CN (1) CN1444565A (no)
AT (1) ATE307804T1 (no)
AU (1) AU2001280813A1 (no)
BR (1) BR0112746A (no)
CA (1) CA2417426A1 (no)
DE (1) DE60114424T2 (no)
EC (1) ECSP034453A (no)
ES (1) ES2251501T3 (no)
HU (1) HUP0301699A3 (no)
IL (1) IL153547A0 (no)
IS (1) IS6695A (no)
MX (1) MXPA03000686A (no)
NO (1) NO20030393L (no)
NZ (1) NZ523271A (no)
PL (1) PL361233A1 (no)
RU (1) RU2003103706A (no)
WO (1) WO2002008199A2 (no)
ZA (1) ZA200300039B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030092107A (ko) * 2001-04-24 2003-12-03 메사추세츠 인스티튜트 오브 테크놀로지 탄소-헤테로원자 및 탄소-탄소 결합을 형성하는 구리-촉매방법
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
JP2006501159A (ja) * 2002-05-31 2006-01-12 ロデイア・シミ 炭素−炭素結合又は炭素−ヘテロ原子結合の形成方法
AU2003257062A1 (en) 2002-08-02 2004-02-23 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
CN1984872A (zh) * 2004-07-16 2007-06-20 帝斯曼知识产权资产管理有限公司 制备(杂)芳胺的方法
KR102107954B1 (ko) * 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2015171951A1 (en) * 2014-05-07 2015-11-12 The Regents Of The University Of Colorado, A Body Corporate 2-(4-aryl-1h-imidazol-1-yl)aniline compounds
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
EP3658144B1 (en) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
AU2019280850C1 (en) 2018-06-06 2025-02-13 Intra-Cellular Therapies, Inc. Novel salts and crystals
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ-セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ-カルボリンの合成
WO2021007245A1 (en) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372658A (ja) 1986-09-17 1988-04-02 Sumitomo Chem Co Ltd ニトロジフエニルアミン類の製造方法
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
NZ523271A (en) 2005-01-28
CA2417426A1 (en) 2002-01-31
ES2251501T3 (es) 2006-05-01
CN1444565A (zh) 2003-09-24
JP2004504384A (ja) 2004-02-12
NO20030393L (no) 2003-03-24
EP1307431A2 (en) 2003-05-07
WO2002008199A3 (en) 2002-06-13
WO2002008199A2 (en) 2002-01-31
ATE307804T1 (de) 2005-11-15
RU2003103706A (ru) 2004-08-10
DE60114424D1 (de) 2005-12-01
MXPA03000686A (es) 2003-06-06
HUP0301699A2 (hu) 2003-12-29
US6541639B2 (en) 2003-04-01
IS6695A (is) 2003-01-22
AU2001280813A1 (en) 2002-02-05
PL361233A1 (en) 2004-10-04
IL153547A0 (en) 2003-07-06
ZA200300039B (en) 2004-04-02
KR20030060872A (ko) 2003-07-16
US20020099225A1 (en) 2002-07-25
BR0112746A (pt) 2003-09-09
ECSP034453A (es) 2003-03-31
DE60114424T2 (de) 2006-07-27
HUP0301699A3 (en) 2004-03-29
EP1307431B1 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
NO20030393L (no) Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler
PT1131318E (pt) Processo para a producao de pirazoles 5-substituidos utilizando ditietanos
PL372799A1 (en) New compounds
EE05015B1 (et) Makseterminaliseade mgipunktiseadme hendamiseks, maksessteem ja makseprotseduuri teostamise meetod
GB0130341D0 (en) Compounds
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
IL161966A0 (en) Aryloxyphenyl and arylsulfanylphenyl
MXPA03008485A (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
MY137541A (en) Polymerization catalyst activators, method of preparing, and their use in polymerization processes
GB0011358D0 (en) Novel use
IT1311813B1 (it) Procedimento ed apparecchiatura per la fabbricazione di lastre inmateriale lapideo.
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
DK1200408T3 (da) Vedhæftningsmiddel
BG100248A (bg) Инхибитори на скваленсинтетаза
NO20033921L (no) Inhibitor av monoaminopptak
IS2273B (is) Aðferð fyrir nýsmíðina á HIV próteasa lötum
IT1290712B1 (it) Procedimento per la produzione di lastre multistrato, relativo impianto di produzione e lastre multistrato
DK1086114T3 (da) Morfin-6-glucuronidsyntese
PT1387837E (pt) Novos derivados de azole e de triazole, processo para a sua preparacao e sua aplicacao como medicamentos anti-fungicos
WO2002070540A3 (en) Peptide deformylase inhibitors
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
WO2002070653A3 (en) Peptide deformylase inhibitors
DE60232650D1 (de) Peptiddeformylaseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application